New heart valve repair device put to the test in Placebo-Controlled trial

NCT ID NCT07133386

Not yet recruiting Symptom relief Sponsor: Barts & The London NHS Trust Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether the TriClip device, which repairs a leaky tricuspid valve without open surgery, can improve daily life for people with severe tricuspid regurgitation. 150 participants will be randomly assigned to receive either the TriClip or a placebo procedure. The main goal is to see if those who get the device report better health status after one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TriClip device (transcatheter edge-to-edge repair)
What this could lead to: If it works, this could provide a new, less invasive option to improve quality of life for people with severe tricuspid regurgitation.
What could go wrong: This is a relatively small, early-stage trial with a placebo control, so results may not confirm benefit. The procedure also carries risks like bleeding or device complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRICUSPID REGURGITATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

tricuspid valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRICUSPID REGURGITATION

Contacts and locations

Locations

St Bartholomew's Hospital

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.